Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Arch Biopartners received central IRB approval for its Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI).
Arch Biopartners received central IRB approval for its Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI).
Amarin presented new REDUCE-IT data at ESC Congress 2026, highlighting insights on treatment adherence, lipoprotein(a) biology, and mechanistic pathways of eicosapentaenoic acid (EPA).
Amarin presented new REDUCE-IT data at ESC Congress 2026, highlighting insights on treatment adherence, long-term outcomes, and mechanistic pathways of icosapent ethyl (IPE).
C1 Fund deployed $41.3M of its $53.3M IPO proceeds into 11 portfolio companies by June 30, 2026, focusing on late-stage digital asset services and technology.
Agiloft launched 'The Advantage Is in Your Contracts' campaign, sponsoring multiple players during the 2026 US Open Tennis Championships from August 23 to September 14.
The National Police Association (NPA) is urging supporters to sign a petition demanding the NYPD Detectives' Endowment Association (DEA) reject dental benefit cuts for retired detectives.
Xeriant, Inc. has initiated commercial production of NexBoard™, its patented universal construction panel, partnering with a high-volume contract manufacturer.
Xeriant, Inc. has initiated commercial production of NexBoard™, its patented universal construction panel, partnering with a high-volume contract manufacturer.
